Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study

Last updated: December 24, 2013
Sponsor: Novartis Pharmaceuticals
Overall Status: Completed

Phase

3

Condition

Joint Injuries

Arthritis And Arthritic Pain (Pediatric)

Collagen Vascular Diseases

Treatment

N/A

Clinical Study ID

NCT01029652
CACZ885H2356
CACZ885H2356E2
2009-015018-23
CACZ885H2356E1
  • Ages 18-85
  • All Genders

Study Summary

The purpose of the 12-week core study was to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent flares of gout for whom non-steroidal anti-inflammatory drugs (NSAIDs) and/ or colchicine are contraindicated, not tolerated, or ineffective. The efficacy of canakinumab was compared to the corticosteroid triamcinolone acetonide.

The purpose of the first 12-week extension study was to collect additional safety, tolerability and efficacy data in patients who have completed the core study CACZ885H2356.

The purpose of the second 48 week open-label extension study was to collect additional long-term safety and tolerability data in patients who have completed the first extension study CACZ885H2356E1.

Eligibility Criteria

Inclusion

Core Study: Inclusion criteria:

  • Meeting the American College of Rheumatology (ACR) 1977 preliminary criteria for theclassification of acute arthritis of primary gout

  • Onset of current acute gout flare within 5 days prior to study entry

  • Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS)

  • History of ≥ 3 gout flares within the 12 months prior to study entry

  • Contraindication, intolerance, or lack of efficacy for non-steroidal anti-inflammatorydrugs (NSAIDs) and/or colchicine

Exclusion

Exclusion criteria:

  • Rheumatoid arthritis, evidence/suspicion of infectious/septic arthritis, or otheracute inflammatory arthritis

  • Presence of severe renal function impairment

  • Use of specified pain relief medications or biologics ( corticosteroids, narcotics,paracetamol/acetominophen, ibuprofen, colchicine, IL-blocker, and tumor necrosisfactor inhibitor) within specified periods prior to study entry

  • Live vaccinations within 3 months prior to randomization

  • Requirement for administration of antibiotics against latent tuberculosis (TB)

  • Refractory heart failure (Stage D)

  • Unstable cardiac arrhythmias or unstable symptomatic coronary ischemia

  • Any active or recurrent bacterial, fungal, or viral infection Extension Study 1: Inclusion Completion of the Core study. A patient was defined as completing the core studyif they completed the study up to and including visit 7. Exclusion

  • Continuation in this extension study was considered inappropriate by the treatingphysician. Extension Study 2: Inclusion Completed of the first extension study CACZ885H2356E1. A patient was defined ascompleting the first extension study if they completed the study up to and including Visit 10). Exclusion

-Continuation in this extension study was considered inappropriate by the treatingphysician Other protocol-defined inclusion-exclusion criteria applied to the core and extensionstudies.

Study Design

Total Participants: 230
Study Start date:
December 01, 2009
Estimated Completion Date:
October 31, 2010

Study Description

Masking:

Core: Double Blind (Subject, Investigator) Extension 1: Double Blind (Subject, Investigator) Extension 2: Open-label, terminated

Connect with a study center

  • Novartis Investigative Site

    Darlinghurst, New South Wales
    Australia

    Site Not Available

  • Novartis Investigative Site

    Fitzroy, Victoria
    Australia

    Site Not Available

  • Novartis Investigative Site

    Heidelberg, Victoria
    Australia

    Site Not Available

  • Novartis Investigative Site

    Daw Park SA,
    Australia

    Site Not Available

  • Novartis Investigative site

    Gozee,
    Belgium

    Site Not Available

  • Novartis Investigative Site

    Mount Pearl, Newfoundland and Labrador
    Canada

    Site Not Available

  • Novartis Investigative site

    St-John's, Newfoundland and Labrador
    Canada

    Site Not Available

  • Novartis Investigative site

    Hamilton, Ontario
    Canada

    Site Not Available

  • Novartis Investigative site

    Barranquilla,
    Colombia

    Site Not Available

  • Novartis Investigative site

    Bogota,
    Colombia

    Site Not Available

  • Novartis Investigative site

    Bucaramanga,
    Colombia

    Site Not Available

  • Novartis Investigative site

    Parnu,
    Estonia

    Site Not Available

  • Novartis Investigative site

    Tallinn,
    Estonia

    Site Not Available

  • Novartis Investigative site

    Tartu,
    Estonia

    Site Not Available

  • Novartis Investigative Site

    Bayreuth,
    Germany

    Site Not Available

  • Novartis Investigative Site

    Berlin,
    Germany

    Site Not Available

  • Novartis Investigative Site

    Leipzig,
    Germany

    Site Not Available

  • Novartis Investigative Site

    Loehne,
    Germany

    Site Not Available

  • Novartis Investigative Site

    Magdeburg,
    Germany

    Site Not Available

  • Novartis Investigative site

    Munich,
    Germany

    Site Not Available

  • Novartis Investigative Site

    Guatemala City,
    Guatemala

    Site Not Available

  • Novartis Investigative Site

    Riga,
    Latvia

    Site Not Available

  • Novartis Investigative Site

    Valmiera,
    Latvia

    Site Not Available

  • Novartis Investigative Site

    Kaunas,
    Lithuania

    Site Not Available

  • Novartis Investigative Site

    Kedainiai,
    Lithuania

    Site Not Available

  • Novartis Investigative site

    Klaipeda,
    Lithuania

    Site Not Available

  • Novartis Investigative Site

    Siauliai,
    Lithuania

    Site Not Available

  • Novartis Investigative Site

    Vilnius,
    Lithuania

    Site Not Available

  • Novartis Investigative site

    Culiacan,
    Mexico

    Site Not Available

  • Novartis Investigative site

    Guadalajara,
    Mexico

    Site Not Available

  • Novartis Investigative site

    Mexicali,
    Mexico

    Site Not Available

  • Novartis Investigative site

    Oslo,
    Norway

    Site Not Available

  • Novartis Investigative site

    Katowice,
    Poland

    Site Not Available

  • Novartis Investigative site

    Kutno,
    Poland

    Site Not Available

  • Novartis Investigative site

    Lublin,
    Poland

    Site Not Available

  • Novartis Investigative Site

    Wroclaw,
    Poland

    Site Not Available

  • Novartis Investigative site

    Chelyabinsk,
    Russian Federation

    Site Not Available

  • Novartis Investigative site

    Ekaterinburg,
    Russian Federation

    Site Not Available

  • Novartis Investigative site

    Moscow,
    Russian Federation

    Site Not Available

  • Novartis Investigative site

    Petrozavodsk,
    Russian Federation

    Site Not Available

  • Novartis Investigative Site

    St. Petersburg,
    Russian Federation

    Site Not Available

  • Novartis Investigative site

    Tula,
    Russian Federation

    Site Not Available

  • Novartis Investigative site

    Tver,
    Russian Federation

    Site Not Available

  • Novartis Investigative site

    Yaroslavl,
    Russian Federation

    Site Not Available

  • Novartis Investigative site

    Yekaterinburg,
    Russian Federation

    Site Not Available

  • Novartis Investigative site

    Singapore,
    Singapore

    Site Not Available

  • Novartis Investigative Site

    Goeteborg,
    Sweden

    Site Not Available

  • Novartis Investigative site

    Stockholm,
    Sweden

    Site Not Available

  • Novartis Investigative Site

    Lausanne,
    Switzerland

    Site Not Available

  • Novartis Investigative site

    Adana,
    Turkey

    Site Not Available

  • Novartis Investigative site

    Ankara,
    Turkey

    Site Not Available

  • Novartis Investigative site

    Etlik,
    Turkey

    Site Not Available

  • Novartis Investigative Site

    Manisa,
    Turkey

    Site Not Available

  • Novartis Investigative Site

    Donetsk,
    Ukraine

    Site Not Available

  • Novartis Investigative Site

    Kyiv,
    Ukraine

    Site Not Available

  • Novartis Investigative Site

    Lviv,
    Ukraine

    Site Not Available

  • Novartis Investigative Site

    Zaporizhzhya,
    Ukraine

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.